Stage 4S Neuroblastoma
暂无分享,去创建一个
F. Hazard | A. Naranjo | J. Gastier-Foster | J. Maris | H. Shimada | W. London | M. Hogarty | B. Chiu | N. Ikegaki | S. Cohn | Julie R. Park | Asuka Kawano | B. Labarre
[1] A. Naranjo,et al. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Maris,et al. Rare MYC-amplified Neuroblastoma With Large Cell Histology , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[3] G. Brodeur. Spontaneous regression of neuroblastoma , 2018, Cell and Tissue Research.
[4] A. Look,et al. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group , 2017, Oncotarget.
[5] A. Look,et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study , 2015, British Journal of Cancer.
[6] H. Beltran. The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential , 2014, Molecular Cancer Research.
[7] A. Look,et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group , 2013, Cancer.
[8] C. Dang. MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.
[9] A. Look,et al. Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee , 2013, Pediatric blood & cancer.
[10] Jan Koster,et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.
[11] R. Stallings,et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression , 2012, Nature Genetics.
[12] S. Monti,et al. Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.
[13] J Khan,et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee , 2009, British Journal of Cancer.
[14] R. Beijersbergen,et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.
[15] F. Méchinaud,et al. Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP) , 2003, British Journal of Cancer.
[16] Hiroyuki Shimada,et al. Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups , 2002, Cancer.
[17] D. Stram,et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Hiroyuki Shimada,et al. Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.
[19] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[20] K. Matthay. Stage 4S neuroblastoma: what makes it special? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Look,et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Max M. van Noesel,et al. Neuroblastoma 4S , 1997, Cancer.
[23] A. Evans,et al. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. , 1996, Medical and pediatric oncology.
[24] J. Hata,et al. Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases. , 1996, Human pathology.
[25] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[26] P. Bruzzi,et al. Disseminated neuroblastoma (stage IV and IV‐S) in the first year of life. Outcome related to age and stage , 1992, Cancer.
[27] C. R. Pinkerton,et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. , 1988, Progress in clinical and biological research.
[28] K. Matthay,et al. Complete pathologic maturation and regression of stage ivs neuroblastoma without treatment , 1988, Cancer.
[29] R. Kennett,et al. Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[30] B. A. Cook,et al. The prognostic significance of age and pattern of metastases in stage IV‐S neuroblastoma , 1986, Cancer.
[31] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .